Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial
Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzu...
Saved in:
| Published in | The lancet oncology Vol. 20; no. 1; pp. 43 - 56 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Elsevier Ltd
01.01.2019
Elsevier Limited |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.
iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of cycle 1 and on day 1 of subsequent 28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same obinutuzumab regimen). Allocation concealment was achieved using an interactive web response system. Patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov (NCT02264574), and patient enrolment is complete.
Between Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a median follow-up of 31·3 months (IQR 29·4–33·2), median progression-free survival was significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33·6–non-estimable]) than in the chlorambucil plus obinutuzumab group (19·0 months [15·1–22·1]; hazard ratio 0·23; 95% CI 0·15–0·37; p<0·0001). Estimated 30-month progression-free survival was 79% (95% CI 70–85) in the ibrutinib plus obinutuzumab group and 31% (23–40) in the chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin).
Ibrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features and provides an alternative first-line treatment option for these patients.
Pharmacyclics LLC, an AbbVie Company, and Janssen Research and Development. |
|---|---|
| AbstractList | Summary Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma. Methods iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of cycle 1 and on day 1 of subsequent 28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same obinutuzumab regimen). Allocation concealment was achieved using an interactive web response system. Patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov (NCT02264574), and patient enrolment is complete. Findings Between Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a median follow-up of 31·3 months (IQR 29·4–33·2), median progression-free survival was significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33·6–non-estimable]) than in the chlorambucil plus obinutuzumab group (19·0 months [15·1–22·1]; hazard ratio 0·23; 95% CI 0·15–0·37; p<0·0001). Estimated 30-month progression-free survival was 79% (95% CI 70–85) in the ibrutinib plus obinutuzumab group and 31% (23–40) in the chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin). Interpretation Ibrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features and provides an alternative first-line treatment option for these patients. Funding Pharmacyclics LLC, an AbbVie Company, and Janssen Research and Development. Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.BACKGROUNDBoth single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma.iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of cycle 1 and on day 1 of subsequent 28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same obinutuzumab regimen). Allocation concealment was achieved using an interactive web response system. Patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov (NCT02264574), and patient enrolment is complete.METHODSiLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of cycle 1 and on day 1 of subsequent 28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same obinutuzumab regimen). Allocation concealment was achieved using an interactive web response system. Patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov (NCT02264574), and patient enrolment is complete.Between Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a median follow-up of 31·3 months (IQR 29·4-33·2), median progression-free survival was significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33·6-non-estimable]) than in the chlorambucil plus obinutuzumab group (19·0 months [15·1-22·1]; hazard ratio 0·23; 95% CI 0·15-0·37; p<0·0001). Estimated 30-month progression-free survival was 79% (95% CI 70-85) in the ibrutinib plus obinutuzumab group and 31% (23-40) in the chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin).FINDINGSBetween Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a median follow-up of 31·3 months (IQR 29·4-33·2), median progression-free survival was significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33·6-non-estimable]) than in the chlorambucil plus obinutuzumab group (19·0 months [15·1-22·1]; hazard ratio 0·23; 95% CI 0·15-0·37; p<0·0001). Estimated 30-month progression-free survival was 79% (95% CI 70-85) in the ibrutinib plus obinutuzumab group and 31% (23-40) in the chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin).Ibrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features and provides an alternative first-line treatment option for these patients.INTERPRETATIONIbrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features and provides an alternative first-line treatment option for these patients.Pharmacyclics LLC, an AbbVie Company, and Janssen Research and Development.FUNDINGPharmacyclics LLC, an AbbVie Company, and Janssen Research and Development. Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma. iLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of cycle 1 and on day 1 of subsequent 28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same obinutuzumab regimen). Allocation concealment was achieved using an interactive web response system. Patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov (NCT02264574), and patient enrolment is complete. Between Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a median follow-up of 31·3 months (IQR 29·4-33·2), median progression-free survival was significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33·6-non-estimable]) than in the chlorambucil plus obinutuzumab group (19·0 months [15·1-22·1]; hazard ratio 0·23; 95% CI 0·15-0·37; p<0·0001). Estimated 30-month progression-free survival was 79% (95% CI 70-85) in the ibrutinib plus obinutuzumab group and 31% (23-40) in the chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin). Ibrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features and provides an alternative first-line treatment option for these patients. Pharmacyclics LLC, an AbbVie Company, and Janssen Research and Development. SummaryBackgroundBoth single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments in chronic lymphocytic leukaemia. We compared the efficacy of the combination of ibrutinib plus obinutuzumab with chlorambucil plus obinutuzumab in first-line chronic lymphocytic leukaemia or small lymphocytic lymphoma. MethodsiLLUMINATE is a multicentre, randomised, open-label, phase 3 trial done at 74 academic and community hospitals in Australia, Canada, Israel, New Zealand, Russia, Turkey, the EU, and the USA in patients with previously untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma, either aged 65 years or older or younger than 65 years with coexisting conditions. Patients were randomly assigned (1:1) using a blocked randomisation schedule, stratified by Eastern Cooperative Oncology Group performance status and cytogenetics, to receive ibrutinib plus obinutuzumab (oral ibrutinib [420 mg once daily continuously] combined with intravenous obinutuzumab [100 mg on day 1, 900 mg on day 2, 1000 mg on day 8, and 1000 mg on day 15 of cycle 1 and on day 1 of subsequent 28-day cycles, for a total of six cycles]) or chlorambucil plus obinutuzumab (oral chlorambucil [0·5 mg/kg bodyweight on days 1 and 15 of each 28-day cycle for six cycles] combined with the same obinutuzumab regimen). Allocation concealment was achieved using an interactive web response system. Patients and investigators were not masked to treatment assignment. The primary endpoint was progression-free survival assessed by a masked independent review committee in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov ( NCT02264574), and patient enrolment is complete. FindingsBetween Oct 6, 2014, and Oct 12, 2015, 229 patients were enrolled and randomly assigned to receive ibrutinib plus obinutuzumab (n=113) or chlorambucil plus obinutuzumab (n=116). After a median follow-up of 31·3 months (IQR 29·4–33·2), median progression-free survival was significantly longer in the ibrutinib plus obinutuzumab group (median not reached [95% CI 33·6–non-estimable]) than in the chlorambucil plus obinutuzumab group (19·0 months [15·1–22·1]; hazard ratio 0·23; 95% CI 0·15–0·37; p<0·0001). Estimated 30-month progression-free survival was 79% (95% CI 70–85) in the ibrutinib plus obinutuzumab group and 31% (23–40) in the chlorambucil plus obinutuzumab group. The most common grade 3 or 4 adverse events in both groups were neutropenia and thrombocytopenia. Serious adverse events occurred in 65 (58%) of 113 patients treated with ibrutinib plus obinutuzumab and 40 (35%) of 115 patients treated with chlorambucil plus obinutuzumab. Ibrutinib or chlorambucil treatment-related deaths were reported in one (1%) of 113 patients in the ibrutinib plus obinutuzumab group (sudden death) and one (1%) of 115 patients in the chlorambucil plus obinutuzumab group (neuroendocrine carcinoma of the skin). InterpretationIbrutinib plus obinutuzumab is an efficacious and safe chemotherapy-free combination treatment in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma independent of high-risk features and provides an alternative first-line treatment option for these patients. FundingPharmacyclics LLC, an AbbVie Company, and Janssen Research and Development. |
| Author | Flinn, Ian W Novak, Jan Ben-Yehuda, Dina Zhou, Cathy Samoilova, Olga Hsu, Emily Anz, Bertrand Larratt, Loree Moreno, Carol Lih, Chih-Jian Simkovic, Martin Gribben, John G Greil, Richard Strugov, Vladimir Tedeschi, Alessandra Gill, Devinder James, Danelle F Clow, Fong Styles, Lori Demirkan, Fatih |
| Author_xml | – sequence: 1 givenname: Carol surname: Moreno fullname: Moreno, Carol email: cmorenoa@santpau.cat organization: Department of Hematology, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain – sequence: 2 givenname: Richard surname: Greil fullname: Greil, Richard organization: Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute, Cancer Cluster Salzburg, Salzburg, Austria – sequence: 3 givenname: Fatih surname: Demirkan fullname: Demirkan, Fatih organization: Dokuz Eylul University, Izmir, Turkey – sequence: 4 givenname: Alessandra surname: Tedeschi fullname: Tedeschi, Alessandra organization: ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy – sequence: 5 givenname: Bertrand surname: Anz fullname: Anz, Bertrand organization: Tennessee Oncology, Chattanooga, TN, USA – sequence: 6 givenname: Loree surname: Larratt fullname: Larratt, Loree organization: University of Alberta, Edmonton, AB, Canada – sequence: 7 givenname: Martin surname: Simkovic fullname: Simkovic, Martin organization: University Hospital Hradec Kralove, Charles University, Hradec Kralove, Czech Republic – sequence: 8 givenname: Olga surname: Samoilova fullname: Samoilova, Olga organization: Nizhny Novogorod Regional Clinical Hospital, Nizhny Novogorod, Russia – sequence: 9 givenname: Jan surname: Novak fullname: Novak, Jan organization: University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University, Prague, Czech Republic – sequence: 10 givenname: Dina surname: Ben-Yehuda fullname: Ben-Yehuda, Dina organization: Department of Hematology, Hadassah Medical Center, Hebrew University of Jerusalem, The Faculty of Medicine, Jerusalem, Israel – sequence: 11 givenname: Vladimir surname: Strugov fullname: Strugov, Vladimir organization: Almazov National Medical Research Centre, St Petersburg, Russia – sequence: 12 givenname: Devinder surname: Gill fullname: Gill, Devinder organization: Princess Alexandra Hospital, Brisbane, QLD, Australia – sequence: 13 givenname: John G surname: Gribben fullname: Gribben, John G organization: Barts Cancer Institute, Queen Mary University of London, London, UK – sequence: 14 givenname: Emily surname: Hsu fullname: Hsu, Emily organization: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA – sequence: 15 givenname: Chih-Jian surname: Lih fullname: Lih, Chih-Jian organization: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA – sequence: 16 givenname: Cathy surname: Zhou fullname: Zhou, Cathy organization: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA – sequence: 17 givenname: Fong surname: Clow fullname: Clow, Fong organization: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA – sequence: 18 givenname: Danelle F surname: James fullname: James, Danelle F organization: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA – sequence: 19 givenname: Lori surname: Styles fullname: Styles, Lori organization: Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA, USA – sequence: 20 givenname: Ian W surname: Flinn fullname: Flinn, Ian W organization: Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30522969$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkt1u1DAQhSNURH_gEUCWuNlKG7CdeOOAAFVVgZUWuKC9tmxnonXr2MFOKi3vxrvh7JZerEDlyiPrO2dGM-c4O3DeQZY9J_gVwWTx-jspK5xTXLIZ4acFrjjP2aPsKH2XOSs5P9jWO-QwO47xGmNSEcyeZIcFZpTWi_oo-7VUYRyMMwr1dozIK-PGYfw5dlKhWwgx_em19UF2atTG_oUyDrUmxCG3xgEaAsihAzcg3yZl8M5oZDddv_Z6M0w1jDcSOiPRzKxWV1-WX88uL07fIIm60SYgSQPMUZCu8Z2J0MyR78HlViqwc9SvZQRUpD5G2qfZ41baCM_u3pPs6uPF5fnnfPXt0_L8bJVrhumQE15qtSg4IYumpIUqVKtw1ZCakJYTzRrFgdVYtRQqyaQGjYksack1pZLRsjjJZjvfPvgfI8RBpMk0WCsd-DEKShiracUKltCXe-i1H4NL0yVqQWvOalIk6sUdNaoOGtEH08mwEX8OkwC2A3TwMQZo7xGCxRQAsQ2AmK4rCBfbAIip_ds9nTaDHIxPW5XGPqj-sFNDWuatgSCiNuA0NCaAHkTjzYMO7_ccdIqF0dLewAbi_S6IiFTgncnkQfjWYTJ492-D_xjgN4zs9Ek |
| CitedBy_id | crossref_primary_10_1002_hon_2744 crossref_primary_10_3389_fonc_2023_1098326 crossref_primary_10_1093_jnci_djae245 crossref_primary_10_1007_s11899_021_00637_1 crossref_primary_10_1007_s11864_022_00974_0 crossref_primary_10_1080_10428194_2024_2416574 crossref_primary_10_1097_HS9_0000000000000175 crossref_primary_10_1182_bloodadvances_2022007938 crossref_primary_10_1007_s11864_020_0715_5 crossref_primary_10_1016_j_leukres_2021_106520 crossref_primary_10_3324_haematol_2019_223693 crossref_primary_10_1016_S1470_2045_21_00455_1 crossref_primary_10_1016_j_clml_2020_10_012 crossref_primary_10_26442_18151434_2021_2_200957 crossref_primary_10_1007_s11899_020_00586_1 crossref_primary_10_1016_S2352_3026_21_00336_7 crossref_primary_10_3389_fonc_2021_780085 crossref_primary_10_1080_17474086_2020_1775575 crossref_primary_10_5045_br_2020_S012 crossref_primary_10_1182_blood_2020008164 crossref_primary_10_1182_blood_2020010484 crossref_primary_10_1200_EDBK_238735 crossref_primary_10_1016_j_clml_2020_02_001 crossref_primary_10_1182_blood_2019002841 crossref_primary_10_2217_fon_2022_0112 crossref_primary_10_1007_s11864_023_01103_1 crossref_primary_10_1007_s12254_020_00615_y crossref_primary_10_3389_fonc_2023_1112616 crossref_primary_10_1200_JCO_21_01181 crossref_primary_10_1097_HS9_0000000000000197 crossref_primary_10_2147_OTT_S189032 crossref_primary_10_1007_s00277_020_03994_8 crossref_primary_10_1007_s11033_022_07705_6 crossref_primary_10_3389_fonc_2022_829983 crossref_primary_10_1007_s11596_021_2385_3 crossref_primary_10_1158_1078_0432_CCR_21_1237 crossref_primary_10_1177_20406207221116577 crossref_primary_10_1016_j_clml_2020_02_013 crossref_primary_10_1007_s40266_019_00678_5 crossref_primary_10_1038_s41571_024_00956_1 crossref_primary_10_1080_10428194_2020_1755857 crossref_primary_10_1080_17474086_2023_2271170 crossref_primary_10_1038_s41408_021_00467_7 crossref_primary_10_1200_JCO_20_00491 crossref_primary_10_1182_bloodadvances_2021005083 crossref_primary_10_1016_S2352_3026_20_30291_X crossref_primary_10_1016_j_leukres_2024_107496 crossref_primary_10_1002_hon_2943 crossref_primary_10_1182_blood_2020010146 crossref_primary_10_3390_cancers12051328 crossref_primary_10_20945_2359_3997000000585 crossref_primary_10_56875_2589_0646_1040 crossref_primary_10_2174_1389557522666220325145003 crossref_primary_10_1080_10428194_2024_2449214 crossref_primary_10_1016_S0140_6736_20_30262_2 crossref_primary_10_1080_10428194_2020_1869966 crossref_primary_10_3389_fonc_2021_720704 crossref_primary_10_1182_bloodadvances_2024013474 crossref_primary_10_1002_hem3_74 crossref_primary_10_3389_fonc_2022_837531 crossref_primary_10_3389_fphar_2024_1513913 crossref_primary_10_3389_fonc_2023_1130595 crossref_primary_10_1080_10428194_2021_1984462 crossref_primary_10_1080_14656566_2023_2218545 crossref_primary_10_1182_blood_2021013208 crossref_primary_10_1186_s13045_021_01054_w crossref_primary_10_3324_haematol_2020_251561 crossref_primary_10_1177_20406207221127550 crossref_primary_10_1182_bloodadvances_2024014474 crossref_primary_10_3390_cancers15041018 crossref_primary_10_6004_jnccn_2020_5034 crossref_primary_10_1080_17474086_2024_2391097 crossref_primary_10_3390_cancers12040894 crossref_primary_10_1080_10428194_2022_2098291 crossref_primary_10_1016_j_blre_2021_100824 crossref_primary_10_1016_j_leukres_2022_106945 crossref_primary_10_1200_JCO_19_01718 crossref_primary_10_3390_cancers15041015 crossref_primary_10_1007_s11523_021_00857_8 crossref_primary_10_1080_14728214_2020_1724282 crossref_primary_10_1200_GO_20_00012 crossref_primary_10_1007_s12254_021_00776_4 crossref_primary_10_1080_10428194_2024_2310150 crossref_primary_10_1016_j_clml_2022_07_017 crossref_primary_10_1007_s00277_024_05666_3 crossref_primary_10_1007_s11899_021_00645_1 crossref_primary_10_3390_biomedicines12122902 crossref_primary_10_1016_j_clml_2023_08_002 crossref_primary_10_1007_s40801_022_00332_4 crossref_primary_10_1182_blood_2021013435 crossref_primary_10_36290_xon_2022_029 crossref_primary_10_1016_S0140_6736_20_30372_X crossref_primary_10_1016_j_clml_2021_11_009 crossref_primary_10_1182_bloodadvances_2020002183 crossref_primary_10_3389_fonc_2019_00689 crossref_primary_10_3390_curroncol28050326 crossref_primary_10_1080_10428194_2022_2038372 crossref_primary_10_1038_s41375_023_01830_2 crossref_primary_10_1182_blood_2023022564 crossref_primary_10_3390_cancers14010207 crossref_primary_10_3390_jpm11080764 crossref_primary_10_1016_j_eclinm_2024_102642 crossref_primary_10_1177_2040620721989588 crossref_primary_10_1080_17474086_2020_1697226 crossref_primary_10_1182_hematology_2024000571 crossref_primary_10_2147_PPA_S417180 crossref_primary_10_1002_cam4_3470 crossref_primary_10_1038_s41375_021_01156_x crossref_primary_10_1080_10428194_2022_2053535 crossref_primary_10_1177_2040620720912990 crossref_primary_10_1080_10428194_2020_1864352 crossref_primary_10_1007_s11912_022_01322_z crossref_primary_10_2147_DDDT_S250823 crossref_primary_10_1080_10428194_2019_1688321 crossref_primary_10_3324_haematol_2019_236000 crossref_primary_10_1158_1078_0432_CCR_22_3887 crossref_primary_10_1080_10428194_2019_1680840 crossref_primary_10_1080_16078454_2021_1980690 crossref_primary_10_1186_s12885_022_10223_0 crossref_primary_10_1016_S2152_2650_20_30449_3 crossref_primary_10_1038_s41392_020_0113_2 crossref_primary_10_18632_oncotarget_27691 crossref_primary_10_1007_s00277_021_04536_6 crossref_primary_10_1097_HS9_0000000000000336 crossref_primary_10_1016_j_clml_2022_07_004 crossref_primary_10_1177_2040620721990553 crossref_primary_10_1080_10428194_2022_2148218 crossref_primary_10_1016_j_clml_2021_09_012 crossref_primary_10_1056_EVIDoa2200006 crossref_primary_10_1016_j_clml_2021_09_010 crossref_primary_10_3389_fonc_2020_01439 crossref_primary_10_1097_HS9_0000000000000473 crossref_primary_10_35754_0234_5730_2023_68_1_70_79 crossref_primary_10_3324_haematol_2021_279012 crossref_primary_10_1111_bjh_18075 crossref_primary_10_1016_j_clinthera_2020_08_017 crossref_primary_10_1186_s12935_020_01518_y crossref_primary_10_1016_j_clml_2023_09_001 crossref_primary_10_1111_sji_12931 crossref_primary_10_3390_cancers15143737 crossref_primary_10_1016_j_clml_2021_06_010 crossref_primary_10_1038_s41375_021_01485_x crossref_primary_10_1016_j_critrevonc_2024_104428 crossref_primary_10_1080_10428194_2021_2020779 crossref_primary_10_1182_blood_2021014960 crossref_primary_10_1002_ajh_25766 crossref_primary_10_1186_s13045_022_01353_w crossref_primary_10_1007_s00761_022_01139_2 crossref_primary_10_1007_s00761_019_00655_y crossref_primary_10_1038_s41375_022_01629_7 crossref_primary_10_1007_s11912_019_0819_x crossref_primary_10_1111_bjh_18072 crossref_primary_10_1016_j_leukres_2020_106432 crossref_primary_10_1007_s40258_023_00826_4 crossref_primary_10_3324_haematol_2020_257048 crossref_primary_10_1002_ajh_25595 crossref_primary_10_1016_j_leukres_2023_107016 crossref_primary_10_1182_hematology_2022000343 crossref_primary_10_1056_NEJMra1908213 crossref_primary_10_1007_s00277_021_04746_y crossref_primary_10_3960_jslrt_20014 crossref_primary_10_1182_blood_2020007376 crossref_primary_10_1016_S1470_2045_20_30443_5 crossref_primary_10_3390_cancers17010119 crossref_primary_10_1111_imj_16207 crossref_primary_10_1080_17474086_2020_1796620 crossref_primary_10_1080_17474086_2019_1597703 crossref_primary_10_1111_ejh_13387 crossref_primary_10_1182_hematology_2024000656 crossref_primary_10_3390_pharmaceutics13122201 crossref_primary_10_3960_jslrt_19023 crossref_primary_10_2147_PPA_S289139 crossref_primary_10_1080_21678707_2020_1804860 crossref_primary_10_1016_j_yao_2021_02_020 crossref_primary_10_1097_PPO_0000000000000417 crossref_primary_10_3960_jslrt_20002 crossref_primary_10_1097_PPO_0000000000000537 crossref_primary_10_1177_2040620719891356 crossref_primary_10_1002_ajh_26677 crossref_primary_10_1097_PPO_0000000000000413 crossref_primary_10_1097_PPO_0000000000000534 crossref_primary_10_1111_myc_13676 crossref_primary_10_1097_PPO_0000000000000412 crossref_primary_10_1097_PPO_0000000000000415 crossref_primary_10_1200_JCO_20_02685 crossref_primary_10_1007_s11912_020_0881_4 crossref_primary_10_3390_cancers11121834 crossref_primary_10_1182_hematology_2021000234 crossref_primary_10_1186_s40364_022_00357_5 crossref_primary_10_1001_jama_2023_1946 crossref_primary_10_1080_10428194_2022_2123223 crossref_primary_10_3390_cancers17020268 crossref_primary_10_3389_fonc_2021_651057 crossref_primary_10_1007_s11912_020_0893_0 crossref_primary_10_1097_HS9_0000000000000278 crossref_primary_10_1111_bjh_17184 crossref_primary_10_1182_bloodadvances_2022007317 crossref_primary_10_3390_curroncol30040322 crossref_primary_10_1080_14737140_2023_2288899 crossref_primary_10_1182_hematology_2021000232 crossref_primary_10_18553_jmcp_2021_27_11_1532 crossref_primary_10_1182_hematology_2021000233 crossref_primary_10_1177_1078155220967440 crossref_primary_10_1097_HS9_0000000000000287 crossref_primary_10_1159_000517059 crossref_primary_10_1002_onco_13685 crossref_primary_10_3390_cancers15153859 crossref_primary_10_1007_s44228_022_00015_5 crossref_primary_10_1111_ejh_13396 crossref_primary_10_1002_jha2_638 crossref_primary_10_2147_OTT_S303060 crossref_primary_10_1007_s11899_021_00652_2 crossref_primary_10_1038_s41375_022_01604_2 crossref_primary_10_1080_14712598_2020_1822318 crossref_primary_10_1007_s11899_019_00511_1 crossref_primary_10_1080_10428194_2021_1913144 crossref_primary_10_18553_jmcp_2020_20095 crossref_primary_10_1182_hematology_2020000120 crossref_primary_10_1002_jha2_227 crossref_primary_10_3390_curroncol28060408 crossref_primary_10_1016_j_clml_2019_10_009 crossref_primary_10_3390_cancers15092596 crossref_primary_10_1002_ajh_26367 crossref_primary_10_1200_EDBK_320117 crossref_primary_10_1182_hematology_2019001321 crossref_primary_10_2147_BLCTT_S326627 crossref_primary_10_1080_17425255_2021_1955855 crossref_primary_10_1016_S2152_2650_20_30472_9 crossref_primary_10_1038_s41571_018_0158_0 crossref_primary_10_1093_annonc_mdz053 crossref_primary_10_1097_HS9_0000000000000729 crossref_primary_10_1177_10781552221103820 crossref_primary_10_1080_10428194_2020_1734594 crossref_primary_10_3324_haematol_2020_259432 crossref_primary_10_1159_000509934 crossref_primary_10_1182_blood_2021011993 crossref_primary_10_1016_S2352_3026_21_00241_6 crossref_primary_10_1111_bjh_17031 crossref_primary_10_1016_j_clml_2024_05_009 crossref_primary_10_3389_fimmu_2024_1482715 crossref_primary_10_1016_j_clml_2024_05_019 crossref_primary_10_1097_CCO_0000000000000585 crossref_primary_10_1186_s40164_019_0139_8 crossref_primary_10_1080_14656566_2022_2113384 crossref_primary_10_1016_j_clml_2021_07_022 crossref_primary_10_1159_000533704 crossref_primary_10_1186_s42358_024_00401_y crossref_primary_10_3390_curroncol28010037 crossref_primary_10_1016_j_semcancer_2022_01_009 crossref_primary_10_1007_s40265_021_01657_0 crossref_primary_10_1111_bjh_18118 crossref_primary_10_1182_bloodadvances_2020001678 crossref_primary_10_1016_j_soncn_2021_151177 crossref_primary_10_1097_PPO_0000000000000409 crossref_primary_10_1080_14737140_2020_1829482 crossref_primary_10_1097_PPO_0000000000000408 crossref_primary_10_1002_jha2_322 crossref_primary_10_1097_PPO_0000000000000530 crossref_primary_10_1097_PPO_0000000000000410 crossref_primary_10_1097_PPO_0000000000000531 crossref_primary_10_1097_CCO_0000000000000791 crossref_primary_10_3390_cancers15071996 crossref_primary_10_1200_JCO_22_01028 crossref_primary_10_3390_cells10051088 crossref_primary_10_2217_fon_2023_0436 crossref_primary_10_1007_s11523_019_00635_7 crossref_primary_10_1182_blood_2019_01_896290 crossref_primary_10_1111_bjh_17139 crossref_primary_10_3390_ijms22136665 crossref_primary_10_1002_ajh_27546 crossref_primary_10_1016_j_jval_2022_04_001 crossref_primary_10_1038_s41375_019_0682_7 crossref_primary_10_1111_bjh_17373 crossref_primary_10_1182_blood_2019_04_901116 crossref_primary_10_1038_s41571_019_0239_8 crossref_primary_10_3389_fphar_2021_769315 crossref_primary_10_1080_17474086_2020_1817735 crossref_primary_10_1007_s00108_019_00706_x crossref_primary_10_1016_j_ejmech_2021_114009 crossref_primary_10_1038_s41420_019_0157_7 crossref_primary_10_3390_ijms22063085 crossref_primary_10_1093_oncolo_oyae229 crossref_primary_10_1007_s11886_023_01916_4 crossref_primary_10_1038_s41408_022_00669_7 crossref_primary_10_1182_blood_2020008502 crossref_primary_10_3390_biomedicines13030741 crossref_primary_10_1016_j_annonc_2020_09_019 crossref_primary_10_1158_1078_0432_CCR_22_0964 crossref_primary_10_1200_JCO_19_03355 crossref_primary_10_1111_bjh_16271 crossref_primary_10_1182_hematology_2020000160 crossref_primary_10_4103_joah_joah_17_21 crossref_primary_10_1186_s13045_023_01469_7 crossref_primary_10_3390_cancers13205141 crossref_primary_10_1016_j_ejca_2020_09_031 crossref_primary_10_3390_cancers14194644 crossref_primary_10_1186_s13045_021_01049_7 crossref_primary_10_2217_ijh_2019_0001 crossref_primary_10_1007_s11899_020_00580_7 crossref_primary_10_1002_cam4_2998 crossref_primary_10_3390_cancers13061457 crossref_primary_10_1038_s41571_020_0381_3 crossref_primary_10_1177_10781552221090869 crossref_primary_10_1097_CCO_0000000000000897 crossref_primary_10_3389_fimmu_2021_687458 crossref_primary_10_1056_NEJMoa1815281 crossref_primary_10_1182_blood_2023021959 crossref_primary_10_1182_blood_2022015854 crossref_primary_10_3390_jcm9020593 crossref_primary_10_1080_10428194_2023_2232489 crossref_primary_10_3389_fphar_2022_989830 crossref_primary_10_1111_bjh_17105 crossref_primary_10_1038_s41375_020_01072_6 crossref_primary_10_1080_17474086_2022_2054800 crossref_primary_10_1097_HS9_0000000000000432 crossref_primary_10_2147_JEP_S265284 crossref_primary_10_1038_s41375_020_01009_z crossref_primary_10_1182_blood_2020009617 crossref_primary_10_1007_s10072_022_06297_0 crossref_primary_10_1186_s12885_022_09256_2 crossref_primary_10_1182_blood_2021010845 crossref_primary_10_3390_cancers14194659 crossref_primary_10_1111_bjh_17215 crossref_primary_10_1002_14651858_CD013474_pub2 crossref_primary_10_1182_bloodadvances_2022009594 crossref_primary_10_3390_cancers16183182 crossref_primary_10_1038_s41598_023_36279_x crossref_primary_10_1056_NEJMc1901284 crossref_primary_10_3389_fcell_2023_1270398 crossref_primary_10_2217_fon_2020_0640 crossref_primary_10_1182_hematology_2020000085 crossref_primary_10_1111_bjh_18418 crossref_primary_10_1111_bjh_17326 crossref_primary_10_1200_JCO_20_00979 crossref_primary_10_1016_j_bneo_2024_100022 crossref_primary_10_21320_2500_2139_2024_17_1_37_42 crossref_primary_10_1016_j_blre_2022_100930 crossref_primary_10_1186_s40164_023_00448_5 crossref_primary_10_1080_10428194_2021_1876863 crossref_primary_10_1016_S0140_6736_24_00595_6 crossref_primary_10_1080_14656566_2024_2398603 crossref_primary_10_1182_blood_2019896688 crossref_primary_10_1016_S1470_2045_23_00144_4 crossref_primary_10_1080_13543784_2020_1783239 crossref_primary_10_1182_blood_2019001321 crossref_primary_10_1200_EDBK_279099 crossref_primary_10_1007_s12185_020_02867_0 crossref_primary_10_3390_ijms24129930 crossref_primary_10_3390_cancers13102468 crossref_primary_10_1016_j_blre_2021_100884 crossref_primary_10_4103_ijmpo_ijmpo_36_20 crossref_primary_10_1111_ejh_13973 crossref_primary_10_1016_j_esmoop_2020_100001 crossref_primary_10_1016_j_clml_2019_07_004 crossref_primary_10_3324_haematol_2019_229161 crossref_primary_10_1080_14712598_2022_2145881 crossref_primary_10_1080_10428194_2020_1811271 crossref_primary_10_1016_j_jgo_2023_101602 crossref_primary_10_1111_bjh_17788 crossref_primary_10_1111_bjh_18995 crossref_primary_10_1146_annurev_pathmechdis_012419_032810 crossref_primary_10_1182_bloodadvances_2023010108 crossref_primary_10_1182_blood_2020006949 crossref_primary_10_3390_cancers12030642 crossref_primary_10_1080_14728222_2020_1832465 crossref_primary_10_1200_JCO_21_00807 crossref_primary_10_1016_S2352_3026_19_30113_9 crossref_primary_10_1080_14728214_2021_1966414 crossref_primary_10_1080_10428194_2022_2045597 crossref_primary_10_1016_S2152_2650_21_01202_7 crossref_primary_10_1080_10428194_2022_2087072 crossref_primary_10_1002_mabi_202300375 crossref_primary_10_1182_bloodadvances_2023011327 crossref_primary_10_1182_bloodadvances_2023011569 crossref_primary_10_1182_bloodadvances_2022008068 crossref_primary_10_2144_fsoa_2019_0064 crossref_primary_10_1182_bloodadvances_2021004824 crossref_primary_10_1016_j_hoc_2021_03_005 crossref_primary_10_1182_bloodadvances_2023012221 crossref_primary_10_4103_CRST_CRST_234_20 crossref_primary_10_2217_fon_2022_0456 crossref_primary_10_3390_cancers14030771 crossref_primary_10_1038_s41375_019_0602_x crossref_primary_10_1080_10428194_2021_1957871 crossref_primary_10_1038_s41375_022_01699_7 crossref_primary_10_1186_s13046_021_02115_1 crossref_primary_10_3389_fimmu_2020_594556 crossref_primary_10_18632_oncotarget_26964 crossref_primary_10_1038_s41467_019_14081_6 crossref_primary_10_3390_cancers16061228 crossref_primary_10_1080_03007995_2020_1835851 crossref_primary_10_3390_cancers13133150 crossref_primary_10_1007_s11864_022_00953_5 crossref_primary_10_3389_fonc_2021_668162 crossref_primary_10_1097_CJI_0000000000000471 crossref_primary_10_1016_S2352_3026_20_30433_6 crossref_primary_10_1080_10428194_2022_2056179 crossref_primary_10_1001_jamanetworkopen_2024_14425 crossref_primary_10_3390_life12020283 crossref_primary_10_1177_1078155219853030 crossref_primary_10_21320_2500_2139_2023_16_1_37_45 crossref_primary_10_1016_j_hoc_2021_03_007 crossref_primary_10_1159_000539609 crossref_primary_10_1016_j_hoc_2021_03_009 crossref_primary_10_1016_j_hoc_2021_03_008 crossref_primary_10_3390_cancers15051583 crossref_primary_10_1016_j_clml_2022_04_017 crossref_primary_10_1080_14712598_2020_1734557 crossref_primary_10_1111_bjh_17984 crossref_primary_10_3390_cancers13061280 crossref_primary_10_1182_bloodadvances_2021005725 crossref_primary_10_1080_13543784_2020_1770225 crossref_primary_10_3390_cancers13133134 crossref_primary_10_1016_j_bneo_2024_100006 crossref_primary_10_6004_jnccn_2022_0031 crossref_primary_10_1007_s11523_025_01133_9 crossref_primary_10_1080_14737140_2024_2398483 crossref_primary_10_1002_hon_2695 crossref_primary_10_1080_10428194_2022_2084731 crossref_primary_10_1182_blood_2019_03_901090 crossref_primary_10_1182_blood_2019003686 crossref_primary_10_1182_blood_2021014488 crossref_primary_10_3390_cancers15020507 crossref_primary_10_1080_14740338_2024_2327507 crossref_primary_10_3389_fonc_2020_591577 crossref_primary_10_3390_cancers13133240 crossref_primary_10_35754_0234_5730_2022_67_4_478_490 crossref_primary_10_1080_17474086_2020_1797482 crossref_primary_10_1002_hon_2583 crossref_primary_10_1124_pharmrev_120_000121 |
| Cites_doi | 10.1056/NEJMoa1802917 10.1038/leu.2017.175 10.1182/blood-2017-10-810044 10.1182/blood-2017-12-820910 10.3324/haematol.2018.192328 10.1056/NEJMoa1400376 10.1002/hon.2437_99 10.1200/JCO.2005.03.1021 10.1182/blood-2007-06-093906 10.1182/blood-2014-10-606038 10.1182/blood-2002-06-1822 10.1056/NEJMoa1313984 10.1016/S1470-2045(16)30051-1 10.1186/ar3400 10.1093/annonc/mdv303 10.1016/S0140-6736(10)61381-5 10.1182/blood-2014-01-546150 10.1182/blood-2017-09-806398 10.1182/blood-2015-09-667675 10.1016/S0140-6736(15)60027-7 10.1038/leu.2015.14 10.1056/NEJMoa023143 10.1056/NEJMoa040857 10.1056/NEJMoa1509388 10.1016/S1470-2045(14)71182-9 10.1038/leu.2016.262 10.1016/S1470-2045(16)30212-1 |
| ContentType | Journal Article |
| Copyright | 2019 Elsevier Ltd Elsevier Ltd Copyright © 2019 Elsevier Ltd. All rights reserved. Copyright Elsevier Limited Jan 2019 |
| Copyright_xml | – notice: 2019 Elsevier Ltd – notice: Elsevier Ltd – notice: Copyright © 2019 Elsevier Ltd. All rights reserved. – notice: Copyright Elsevier Limited Jan 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 0TZ 3V. 7RV 7TO 7X7 7XB 88E 8AO 8C1 8C2 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. KB0 M0S M1P NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 |
| DOI | 10.1016/S1470-2045(18)30788-5 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Pharma and Biotech Premium PRO ProQuest Central (Corporate) ProQuest Nursing & Allied Health Database (NC LIVE) Oncogenes and Growth Factors Abstracts ProQuest Health & Medical Collection (NC LIVE) ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Lancet Titles Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Health & Medical Collection Medical Database Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Pharma and Biotech Premium PRO Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) Lancet Titles ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Pharma Collection ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Public Health ProQuest One Academic Eastern Edition ProQuest Nursing & Allied Health Source ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Pharma and Biotech Premium PRO MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-5488 |
| EndPage | 56 |
| ExternalDocumentID | 30522969 10_1016_S1470_2045_18_30788_5 S1470204518307885 1_s2_0_S1470204518307885 |
| Genre | Clinical Trial, Phase III Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Pharmacyclics LLC, an AbbVie Company, and Janssen Research and Development. |
| GroupedDBID | --- --K --M -RU .1- .55 .FO 0R~ 123 1B1 1P~ 1~5 29L 4.4 457 4CK 4G. 53G 5VS 6PF 7-5 71M 7RV 7X7 88E 8AO 8C1 8C2 8FI 8FJ AAEDT AAEDW AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AAQXK AATTM AAWTL AAXKI AAXUO AAYWO ABBQC ABMAC ABMZM ABUWG ABWVN ACGFS ACIEU ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADMUD ADNMO AEIPS AEKER AENEX AEUPX AEVXI AFKRA AFPUW AFRHN AFTJW AFXIZ AGCQF AGHFR AGQPQ AHMBA AIGII AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ ANZVX APXCP ASPBG AVWKF AXJTR AZFZN BENPR BKEYQ BKOJK BNPGV BPHCQ BVXVI CCPQU CS3 DU5 EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EX3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA HMCUK HVGLF HZ~ IHE J1W KOM M1P M41 MO0 N9A NAPCQ O-L O9- OC~ OO- OZT P-8 P-9 P2P PCD PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO PUEGO R2- ROL RPZ SDG SEL SES SPCBC SSH SSZ T5K TLN UKHRP UV1 WOW X7M XBR Z5R 3V. AACTN AFCTW AFKWA AJOXV ALIPV AMFUW RIG SDF ABLVK ABYKQ AHPSJ AJBFU ZA5 AAYXX AGRNS CITATION CGR CUY CVF ECM EIF NPM 0TZ 7TO 7XB 8FK H94 K9. PKEHL PQEST PQUKI PRINS 7X8 |
| ID | FETCH-LOGICAL-c502t-184cb638116d423b3bfb07d1911f81c5db8e590bf2e7a5acec01a4248c22a5243 |
| IEDL.DBID | 7X7 |
| ISSN | 1470-2045 1474-5488 |
| IngestDate | Fri Jul 11 12:30:57 EDT 2025 Wed Aug 13 09:33:38 EDT 2025 Thu Apr 03 07:06:32 EDT 2025 Thu Apr 24 22:51:41 EDT 2025 Tue Jul 01 01:53:19 EDT 2025 Fri Feb 23 02:18:58 EST 2024 Sun Feb 23 10:18:56 EST 2025 Tue Aug 26 16:33:33 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2019 Elsevier Ltd. All rights reserved. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c502t-184cb638116d423b3bfb07d1911f81c5db8e590bf2e7a5acec01a4248c22a5243 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 |
| PMID | 30522969 |
| PQID | 2162985913 |
| PQPubID | 46089 |
| PageCount | 14 |
| ParticipantIDs | proquest_miscellaneous_2155927535 proquest_journals_2162985913 pubmed_primary_30522969 crossref_primary_10_1016_S1470_2045_18_30788_5 crossref_citationtrail_10_1016_S1470_2045_18_30788_5 elsevier_sciencedirect_doi_10_1016_S1470_2045_18_30788_5 elsevier_clinicalkeyesjournals_1_s2_0_S1470204518307885 elsevier_clinicalkey_doi_10_1016_S1470_2045_18_30788_5 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | January 2019 2019 2019-01-00 20190101 |
| PublicationDateYYYYMMDD | 2019-01-01 |
| PublicationDate_xml | – month: 01 year: 2019 text: January 2019 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The lancet oncology |
| PublicationTitleAlternate | Lancet Oncol |
| PublicationYear | 2019 |
| Publisher | Elsevier Ltd Elsevier Limited |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited |
| References | Byrd, Furman, Coutre (bib25) 2015; 125 Hallek, Cheson, Catovsky (bib24) 2008; 111 Brown, Hillmen, O'Brien (bib15) 2018; 32 Rassenti, Huynh, Toy (bib22) 2004; 351 Eichhorst, Fink, Bahlo (bib14) 2016; 17 Stilgenbauer, Schnaiter, Paschka (bib11) 2014; 123 Eichhorst, Robak, Montserrat (bib4) 2015; 26 Burger, Sivina, Ferrajoli (bib26) 2017; 130 Ruella, Kenderian, Shestova (bib29) 2017; 31 Hillmen, Robak, Janssens (bib6) 2015; 385 Hallek, Fischer, Fingerle-Rowson (bib13) 2010; 376 Ahn, Farooqui, Tian (bib19) 2018; 131 Burger, Tedeschi, Barr (bib1) 2015; 373 Crespo, Bosch, Villamor (bib23) 2003; 348 Thompson, Tam, O'Brien (bib12) 2016; 127 Goede, Fischer, Engelke (bib8) 2015; 29 Dimopoulos, Tedeschi, Trotman (bib27) 2018; 378 Byrd, Gribben, Peterson (bib10) 2006; 24 O'Brien, Jones, Coutre (bib16) 2016; 17 Chang, Huang, Francesco (bib28) 2011; 13 Hallek, Cheson, Catovsky (bib9) 2018; 131 (bib7) June 27, 2017 Kipps, Fraser, Coutre (bib17) 2017; 35 Lanham, Hamblin, Oscier, Ibbotson, Stevenson, Packham (bib21) 2003; 101 Byrd, Brown, O'Brien (bib2) 2014; 371 O'Brien, Furman, Coutre (bib3) 2018; 131 Farooqui, Valdez, Martyr (bib18) 2015; 16 Barr, Robak, Owen (bib20) 2018; 103 Goede, Fischer, Busch (bib5) 2014; 370 Brown (10.1016/S1470-2045(18)30788-5_bib15) 2018; 32 Crespo (10.1016/S1470-2045(18)30788-5_bib23) 2003; 348 Dimopoulos (10.1016/S1470-2045(18)30788-5_bib27) 2018; 378 Burger (10.1016/S1470-2045(18)30788-5_bib1) 2015; 373 Eichhorst (10.1016/S1470-2045(18)30788-5_bib14) 2016; 17 Thompson (10.1016/S1470-2045(18)30788-5_bib12) 2016; 127 Hillmen (10.1016/S1470-2045(18)30788-5_bib6) 2015; 385 Hallek (10.1016/S1470-2045(18)30788-5_bib9) 2018; 131 Barr (10.1016/S1470-2045(18)30788-5_bib20) 2018; 103 Ahn (10.1016/S1470-2045(18)30788-5_bib19) 2018; 131 Ruella (10.1016/S1470-2045(18)30788-5_bib29) 2017; 31 Burger (10.1016/S1470-2045(18)30788-5_bib26) 2017; 130 Byrd (10.1016/S1470-2045(18)30788-5_bib2) 2014; 371 Eichhorst (10.1016/S1470-2045(18)30788-5_bib4) 2015; 26 O'Brien (10.1016/S1470-2045(18)30788-5_bib3) 2018; 131 Chang (10.1016/S1470-2045(18)30788-5_bib28) 2011; 13 O'Brien (10.1016/S1470-2045(18)30788-5_bib16) 2016; 17 Farooqui (10.1016/S1470-2045(18)30788-5_bib18) 2015; 16 Goede (10.1016/S1470-2045(18)30788-5_bib8) 2015; 29 Lanham (10.1016/S1470-2045(18)30788-5_bib21) 2003; 101 (10.1016/S1470-2045(18)30788-5_bib7) 2017 Rassenti (10.1016/S1470-2045(18)30788-5_bib22) 2004; 351 Kipps (10.1016/S1470-2045(18)30788-5_bib17) 2017; 35 Hallek (10.1016/S1470-2045(18)30788-5_bib24) 2008; 111 Stilgenbauer (10.1016/S1470-2045(18)30788-5_bib11) 2014; 123 Byrd (10.1016/S1470-2045(18)30788-5_bib25) 2015; 125 Hallek (10.1016/S1470-2045(18)30788-5_bib13) 2010; 376 Goede (10.1016/S1470-2045(18)30788-5_bib5) 2014; 370 Byrd (10.1016/S1470-2045(18)30788-5_bib10) 2006; 24 30614469 - Lancet Oncol. 2019 Jan;20(1):e10 |
| References_xml | – volume: 111 start-page: 5446 year: 2008 end-page: 5456 ident: bib24 article-title: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines publication-title: Blood – volume: 131 start-page: 2745 year: 2018 end-page: 2760 ident: bib9 article-title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL publication-title: Blood – volume: 378 start-page: 2399 year: 2018 end-page: 2410 ident: bib27 article-title: Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia publication-title: N Engl J Med – volume: 17 start-page: 928 year: 2016 end-page: 942 ident: bib14 article-title: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial publication-title: Lancet Oncol – volume: 376 start-page: 1164 year: 2010 end-page: 1174 ident: bib13 article-title: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial publication-title: Lancet – volume: 370 start-page: 1101 year: 2014 end-page: 1110 ident: bib5 article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions publication-title: N Engl J Med – volume: 29 start-page: 1602 year: 2015 end-page: 1604 ident: bib8 article-title: Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study publication-title: Leukemia – volume: 123 start-page: 3247 year: 2014 end-page: 3254 ident: bib11 article-title: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial publication-title: Blood – volume: 373 start-page: 2425 year: 2015 end-page: 2437 ident: bib1 article-title: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia publication-title: N Engl J Med – volume: 26 start-page: v78 year: 2015 end-page: v84 ident: bib4 article-title: Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol – volume: 16 start-page: 169 year: 2015 end-page: 176 ident: bib18 article-title: Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial publication-title: Lancet Oncol – volume: 13 start-page: R115 year: 2011 ident: bib28 article-title: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells publication-title: Arthritis Res Ther – volume: 31 start-page: 246 year: 2017 end-page: 248 ident: bib29 article-title: Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms publication-title: Leukemia – volume: 371 start-page: 213 year: 2014 end-page: 223 ident: bib2 article-title: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia publication-title: N Engl J Med – volume: 385 start-page: 1873 year: 2015 end-page: 1883 ident: bib6 article-title: Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial publication-title: Lancet – volume: 35 start-page: 109 year: 2017 end-page: 111 ident: bib17 article-title: Integrated analysis: outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk prognostic factors publication-title: Hematol Oncol – volume: 101 start-page: 1087 year: 2003 end-page: 1093 ident: bib21 article-title: Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia publication-title: Blood – year: June 27, 2017 ident: bib7 article-title: eUpdate—chronic lymphocytic leukaemia treatment recommendations – volume: 131 start-page: 2357 year: 2018 end-page: 2366 ident: bib19 article-title: Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study publication-title: Blood – volume: 125 start-page: 2497 year: 2015 end-page: 2506 ident: bib25 article-title: Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib publication-title: Blood – volume: 130 start-page: 427 year: 2017 ident: bib26 article-title: Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL) publication-title: Blood – volume: 32 start-page: 83 year: 2018 end-page: 91 ident: bib15 article-title: Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL publication-title: Leukemia – volume: 127 start-page: 303 year: 2016 end-page: 309 ident: bib12 article-title: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia publication-title: Blood – volume: 103 start-page: 1502 year: 2018 end-page: 1510 ident: bib20 article-title: Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 publication-title: Haematologica – volume: 24 start-page: 437 year: 2006 end-page: 443 ident: bib10 article-title: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy publication-title: J Clin Oncol – volume: 131 start-page: 1910 year: 2018 end-page: 1919 ident: bib3 article-title: Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience publication-title: Blood – volume: 348 start-page: 1764 year: 2003 end-page: 1775 ident: bib23 article-title: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia publication-title: N Engl J Med – volume: 17 start-page: 1409 year: 2016 end-page: 1418 ident: bib16 article-title: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study publication-title: Lancet Oncol – volume: 351 start-page: 893 year: 2004 end-page: 901 ident: bib22 article-title: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia publication-title: N Engl J Med – volume: 378 start-page: 2399 year: 2018 ident: 10.1016/S1470-2045(18)30788-5_bib27 article-title: Phase 3 trial of ibrutinib plus rituximab in Waldenstrom's macroglobulinemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1802917 – volume: 32 start-page: 83 year: 2018 ident: 10.1016/S1470-2045(18)30788-5_bib15 article-title: Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL publication-title: Leukemia doi: 10.1038/leu.2017.175 – volume: 131 start-page: 1910 year: 2018 ident: 10.1016/S1470-2045(18)30788-5_bib3 article-title: Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience publication-title: Blood doi: 10.1182/blood-2017-10-810044 – volume: 131 start-page: 2357 year: 2018 ident: 10.1016/S1470-2045(18)30788-5_bib19 article-title: Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study publication-title: Blood doi: 10.1182/blood-2017-12-820910 – volume: 103 start-page: 1502 year: 2018 ident: 10.1016/S1470-2045(18)30788-5_bib20 article-title: Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2 publication-title: Haematologica doi: 10.3324/haematol.2018.192328 – volume: 371 start-page: 213 year: 2014 ident: 10.1016/S1470-2045(18)30788-5_bib2 article-title: Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1400376 – volume: 35 start-page: 109 issue: suppl 2 year: 2017 ident: 10.1016/S1470-2045(18)30788-5_bib17 article-title: Integrated analysis: outcomes of ibrutinib-treated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) with high-risk prognostic factors publication-title: Hematol Oncol doi: 10.1002/hon.2437_99 – volume: 130 start-page: 427 issue: suppl 1 year: 2017 ident: 10.1016/S1470-2045(18)30788-5_bib26 article-title: Randomized trial of ibrutinib versus ibrutinib plus rituximab (Ib+R) in patients with chronic lymphocytic leukemia (CLL) publication-title: Blood – volume: 24 start-page: 437 year: 2006 ident: 10.1016/S1470-2045(18)30788-5_bib10 article-title: Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy publication-title: J Clin Oncol doi: 10.1200/JCO.2005.03.1021 – year: 2017 ident: 10.1016/S1470-2045(18)30788-5_bib7 – volume: 111 start-page: 5446 year: 2008 ident: 10.1016/S1470-2045(18)30788-5_bib24 article-title: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines publication-title: Blood doi: 10.1182/blood-2007-06-093906 – volume: 125 start-page: 2497 year: 2015 ident: 10.1016/S1470-2045(18)30788-5_bib25 article-title: Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib publication-title: Blood doi: 10.1182/blood-2014-10-606038 – volume: 101 start-page: 1087 year: 2003 ident: 10.1016/S1470-2045(18)30788-5_bib21 article-title: Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia publication-title: Blood doi: 10.1182/blood-2002-06-1822 – volume: 370 start-page: 1101 year: 2014 ident: 10.1016/S1470-2045(18)30788-5_bib5 article-title: Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions publication-title: N Engl J Med doi: 10.1056/NEJMoa1313984 – volume: 17 start-page: 928 year: 2016 ident: 10.1016/S1470-2045(18)30788-5_bib14 article-title: First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30051-1 – volume: 13 start-page: R115 year: 2011 ident: 10.1016/S1470-2045(18)30788-5_bib28 article-title: The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells publication-title: Arthritis Res Ther doi: 10.1186/ar3400 – volume: 26 start-page: v78 issue: suppl 5 year: 2015 ident: 10.1016/S1470-2045(18)30788-5_bib4 article-title: Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up publication-title: Ann Oncol doi: 10.1093/annonc/mdv303 – volume: 376 start-page: 1164 year: 2010 ident: 10.1016/S1470-2045(18)30788-5_bib13 article-title: Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61381-5 – volume: 123 start-page: 3247 year: 2014 ident: 10.1016/S1470-2045(18)30788-5_bib11 article-title: Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial publication-title: Blood doi: 10.1182/blood-2014-01-546150 – volume: 131 start-page: 2745 year: 2018 ident: 10.1016/S1470-2045(18)30788-5_bib9 article-title: iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL publication-title: Blood doi: 10.1182/blood-2017-09-806398 – volume: 127 start-page: 303 year: 2016 ident: 10.1016/S1470-2045(18)30788-5_bib12 article-title: Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia publication-title: Blood doi: 10.1182/blood-2015-09-667675 – volume: 385 start-page: 1873 year: 2015 ident: 10.1016/S1470-2045(18)30788-5_bib6 article-title: Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial publication-title: Lancet doi: 10.1016/S0140-6736(15)60027-7 – volume: 29 start-page: 1602 year: 2015 ident: 10.1016/S1470-2045(18)30788-5_bib8 article-title: Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study publication-title: Leukemia doi: 10.1038/leu.2015.14 – volume: 348 start-page: 1764 year: 2003 ident: 10.1016/S1470-2045(18)30788-5_bib23 article-title: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa023143 – volume: 351 start-page: 893 year: 2004 ident: 10.1016/S1470-2045(18)30788-5_bib22 article-title: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa040857 – volume: 373 start-page: 2425 year: 2015 ident: 10.1016/S1470-2045(18)30788-5_bib1 article-title: Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia publication-title: N Engl J Med doi: 10.1056/NEJMoa1509388 – volume: 16 start-page: 169 year: 2015 ident: 10.1016/S1470-2045(18)30788-5_bib18 article-title: Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)71182-9 – volume: 31 start-page: 246 year: 2017 ident: 10.1016/S1470-2045(18)30788-5_bib29 article-title: Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms publication-title: Leukemia doi: 10.1038/leu.2016.262 – volume: 17 start-page: 1409 year: 2016 ident: 10.1016/S1470-2045(18)30788-5_bib16 article-title: Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study publication-title: Lancet Oncol doi: 10.1016/S1470-2045(16)30212-1 – reference: 30614469 - Lancet Oncol. 2019 Jan;20(1):e10 |
| SSID | ssj0017105 |
| Score | 2.6841805 |
| Snippet | Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard first-line treatments... SummaryBackgroundBoth single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard... Summary Background Both single-agent ibrutinib and chlorambucil plus obinutuzumab have shown superior efficacy to chlorambucil monotherapy and are standard... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 43 |
| SubjectTerms | Aged Antibodies, Monoclonal, Humanized - administration & dosage Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cardiac arrhythmia Chemotherapy Chlorambucil Chlorambucil - administration & dosage Chlorambucil - adverse effects Chlorambucil - therapeutic use Chronic lymphocytic leukemia Cytogenetics Dyspnea Female Hematology, Oncology, and Palliative Medicine Humans Hyperglycemia Immunotherapy Inhibitor drugs Intention to Treat Analysis Intravenous administration Kinases Leukemia Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - mortality Lymphoma Male Monoclonal antibodies Mutation Neuroendocrine tumors Neutropenia Neutrophils Oncology Patients Progression-Free Survival Pyrazoles - administration & dosage Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - administration & dosage Pyrimidines - adverse effects Pyrimidines - therapeutic use Skin Skin cancer Survival Targeted cancer therapy Thrombocytopenia Treatment Outcome |
| Title | Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S1470204518307885 https://www.clinicalkey.es/playcontent/1-s2.0-S1470204518307885 https://dx.doi.org/10.1016/S1470-2045(18)30788-5 https://www.ncbi.nlm.nih.gov/pubmed/30522969 https://www.proquest.com/docview/2162985913 https://www.proquest.com/docview/2155927535 |
| Volume | 20 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Lb9QwELaglRAXxLsLpTISh1ba0Nh5mgsq1VYt6q4QdKW9WX5FjcgmS3dzKP-N_8ZMXr20lEsUJfkSKfN5HvZ4hpAPTnAXWG09obIEAhSLi4RCeUYEiiseCNPs8J7O4tN5-HURLboJt3WXVtnrxEZR28rgHPkhZzEXWGwt-Lz65WHXKFxd7VpoPCTbWLoMWZ0shoCLJW0KIwsT38Oy6zc7eA5_DBf3WXoARAfCRHfZprt8z8YGnTwlTzrnkR610n5GHrjyOXk07ZbHX5A_Z_oKiFTmmq6Kek1xb1e9qX_XS6Up5l_ANXMJEbpa6trkxS1P5SXNcvAIPXQ_6ZCGTqsMkE0dXVpcAwMqc73Bc1f_VG6ZK7qfn5_Pp2ezo4vJwSeqaJOp2KR-ujEFg2grYJSzY4r9ujzgnivGdHUJRpQGtOkd8pLMTyYXx6de15_BM5HPNx4Eh0bD-GUstuCV6UBn2k8sRIAsS5mJrE5dJHydcZeoSBlnfKZCHqaGcxXxMHhFtsqqdDuECp2IFCtbpYaF1gSaaW1cYkMV-Zl12YiEvWSk6YqXYw-NQg5ZaihQiQKVLJWNQGU0Ih8H2Kqt3nEfIO7FLvutqaBMJdiX-4DJbUC37lTCWjK55tJv0QgGXYpQQKYDsvN6Wm_mfz662zNTDt-5GSgj8n64DSLGlSBVuqrGZyCQ5BCpwitet4we_g8YAM5FLN78--VvyWPwHUU7G7VLtjZXtXsH_tlG7zWDEI7pMdsj218ms2_f_wIoDjer |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB6VIgEXxE5KgUECqZVi6hmvg4RQVVolNMmFROptOptVq44dmlgo_Cj-Af-NN956aSmX3iLH31jy--Ytnrcg9N4wajwttcNEEkGAou0hIROOYp6ggnpMVRXe40k4mPnfToKTDfS7rYWxaZWtTqwUtS6U_Ua-R0lImW225n1Z_HDs1Ch7utqO0KhpcWzWPyFkW34efgX5fqD06HB6MHCaqQKOCly6ciCkURJYR0iowZeQnkykG2mIW0gSExVoGZuAuTKhJhKBUEa5RPjUjxWlIqC-B-veQXd9D7amrUw_6FJKSFSnTBI_ch3b5v2yYmjve3dxh8S7sLGAoMF1tvA6X7eyeUeP0MPGWcX7Nbseow2TP0H3xs1x_FP0ZygvgLh5KvEiK5fY1pKVq_JXORcS23wPuKbOMmDZXJYqza64K81xkoIH6lh3F3dp77hIAFn17cXZGhhXqPXK_jbluTDzVOCddDSajYeT_enh7icscJUZWaWamj4GA6wLYLDRfWzngznAdZP18eIMjDb2cDWr5Bma3YrknqPNvMjNS4SZjFhsO2nFivhaeZJIqUykfRG4iTZJD_mtZLhqmqXbmR0Z77LirEC5FSgnMa8EyoMe-tjBFnW3kJsAYSt23pbCgvLmYM9uAkZXAc2yUUFLTviScrdGWzDobgsFZNwhGy-r9p7-56HbLTN595zLjdlD77q_QcT25EnkpijtPRC4UoiMYYkXNaO79wMGh1IWsq1_L_4W3R9MxyM-Gk6OX6EH4Ley-kvYNtpcXZTmNfiGK_mm2pAYnd62BvgLX9JxbQ |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1ba9RAFB5qheKLeHe16ggKLWzczCTZZASR0nbp2t1FsAt9m84tNJhN1m6CrD9N8L95Jre-tNaXvi3ZfBPI-eZcMueC0DvDqPG01A4TcQgBiraHhEw4inmCCuoxVVV4T2fDo7n_5TQ43UC_21oYm1bZ6sRKUetc2W_kA0qGlNlma94gbtIivh6MPi9_OHaClD1pbcdp1BQ5NuufEL6tPo0PQNbvKR0dnuwfOc2EAUcFLi0cCG-UBAYSMtTgV0hPxtINNcQwJI6ICrSMTMBcGVMTikAoo1wifOpHilIRUN-Dde-gu6EXRnaPRftdegkJ6_RJ4oeuY1u-X1YPDb51F3dItAubDMgaXGcXr_N7K_s3eoDuN44r3quZ9hBtmOwR2po2R_OP0Z-xvAASZ4nEy7RcYVtXVhblr3IhJLa5H3BNnafAuIUsVZJecVeS4TgBb9Sxri_uUuBxHgOy6uGL0zWwL1frwv425XdhFonAO8lkMp-OZ3snh7sfscBVlmSVdmr6GIyxzoHNRvexnRXmAO9N2sfLczDg2MPV3JInaH4rknuKNrM8M88RZjJkke2qFSnia-VJIqUyofZF4MbaxD3kt5Lhqmmcbud3pLzLkLMC5VagnES8EigPeuhDB1vWnUNuAgxbsfO2LBYUOQfbdhMwvApoVo06WnHCV5S7NdqCQY9bKCCjDtl4XLUn9T8P3W6ZybvnXG7SHnrb_Q0itqdQIjN5ae-BIJZClAxLPKsZ3b0fMD6UsiF78e_F36At2Pt8Mp4dv0T3wIVl9UexbbRZXJTmFbiJhXxd7UeMzm5bAfwF8cB1ow |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Ibrutinib+plus+obinutuzumab+versus+chlorambucil+plus+obinutuzumab+in+first-line+treatment+of+chronic+lymphocytic+leukaemia+%28iLLUMINATE%29%3A+a+multicentre%2C+randomised%2C+open-label%2C+phase+3+trial&rft.jtitle=The+lancet+oncology&rft.au=Moreno%2C+Carol%2C+MD&rft.au=Greil%2C+Richard%2C+Prof&rft.au=Demirkan%2C+Fatih%2C+Prof&rft.au=Tedeschi%2C+Alessandra%2C+MD&rft.date=2019&rft.issn=1470-2045&rft.volume=20&rft.issue=1&rft.spage=43&rft.epage=56&rft_id=info:doi/10.1016%2FS1470-2045%2818%2930788-5&rft.externalDBID=ECK1-s2.0-S1470204518307885&rft.externalDocID=1_s2_0_S1470204518307885 |
| thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F14702045%2FS1470204518X00138%2Fcov150h.gif |